NCX 1000 is a liver-specific NO donor compound derived from ursodeoxycholic acid (UDCA).

Product information

CAS Number: 401519-96-8

Molecular Weight: 685.84

Formula: C38H55NO10

Chemical Name: 2-methoxy-4-{3-[4-(nitrooxy)butoxy]-3-oxoprop-1-en-1-yl}phenyl 4-{4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl}pentanoate

Smiles: CC(CCC(=O)OC1=CC=C(C=CC(=O)OCCCCO[N+]([O-])=O)C=C1OC)C1CCC2C3C(CCC21C)C1(C)CCC(O)CC1CC3O

InChiKey: WTAVOESJEWSDJC-NTEUORMPSA-N

InChi: InChI=1S/C38H55NO10/c1-24(28-10-11-29-36-30(16-18-38(28,29)3)37(2)17-15-27(40)22-26(37)23-31(36)41)7-13-35(43)49-32-12-8-25(21-33(32)46-4)9-14-34(42)47-19-5-6-20-48-39(44)45/h8-9,12,14,21,24,26-31,36,40-41H,5-7,10-11,13,15-20,22-23H2,1-4H3/b14-9+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

NCX-1000 (15 mg/kg, p.o.) prevents ascite formation, reduces collagen deposition in CCl4-treated rats. NCX-1000 administration almost completely reverts portal hypertension induced by CCl4, and reduces portal pressure in cirrhotic rats. NCX-1000 reverts HSC contraction induced by FCS, and also inhibits MCP-1 release from HSCs stimulated with TNF-α and IFN-γ. NCX-1000 (28 mg/kg, p.o.) decreases portal pressure without affecting mean arterial pressure and heart rate in rats. NCX-1000 also reduces vasoconstriction by 60% caused by 30 μM NE in rats. Administration of NCX-1000 to BDL and sham operated rats results in a similar increase of nitrite/nitrate and cGMP concentrations in the liver.

Products are for research use only. Not for human use.